Consumers and health professionals are advised that the information below does not apply to the 2019 formulation of the trivalent influenza vaccine Fluad.
The vaccine’s sponsor, Seqirus, has changed the materials used in the sheath covering the needle and it no longer contains latex.
Please note there were no safety concerns regarding the vaccine itself. The latex used in last year’s formulation posed a small risk for those with an allergy to latex.
Fluad trivalent influenza vaccine
Safety advisory – risk to patients with latex allergy
19 April 2018
Consumers and health professionals are advised that, for the 2018 influenza season, natural rubber latex is present in the sheath covering the needle of trivalent influenza vaccine Fluad. Fluad is available for people aged 65 years and over through the ³Ô¹ÏÍøÕ¾ Immunisation Program (NIP).
While reactions to latex are rare, anyone who has a severe allergy to latex should not receive Fluad. Patients 65 and over can still be safely vaccinated with an alternative trivalent influenza vaccine, Fluzone High-Dose through the NIP.
Please note there are no safety concerns regarding the vaccine itself.
The sponsor of Fluad, Seqirus, has committed to updating the Product Information of this vaccine accordingly.
Information for consumers
If you, or someone you provide care for, has an allergy to latex, advise your health professional of this fact before receiving any influenza vaccination.
There is an alternative product available on the NIP for those aged 65 and over.
If you have any questions or concerns about this issue, talk to your health professional.
Information for health professionals
If you are vaccinating patients with Fluad, please be aware of this issue and advise patients accordingly. Reassure patients that reactions to latex are rare.
Before administering Fluad, confirm with patients that they are not allergic to latex.
As with all vaccinations, be prepared to treat immediate allergic reactions, including potential anaphylaxis.
If you have any questions or concerns about this issue, contact Seqirus on 1800 642 865.
Reporting problems
Consumers and health professionals are encouraged to . Your report will contribute to the TGA’s monitoring of these products.
The TGA cannot give advice about an individual’s medical condition. You are strongly encouraged to talk with a health professional if you are concerned about a possible adverse event associated with a medicine or vaccine.
